• Keine Ergebnisse gefunden

The use of patient-reported outcome measures (PROMs) in rare diseases and implications for health technology assessment (HTA) The Patient Amanda Whittal

N/A
N/A
Protected

Academic year: 2022

Aktie "The use of patient-reported outcome measures (PROMs) in rare diseases and implications for health technology assessment (HTA) The Patient Amanda Whittal"

Copied!
2
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

The use of patient-reported outcome measures (PROMs) in rare diseases and implications for health technology assessment (HTA)

The Patient

Amanda Whittal

1*

, Michela Meregaglia

1

, Elena Nicod

1

1

Research Centre on Health and Social Care Management (CERGAS) SDA Bocconi School of Management

Via Sarfatti 10, 20136 Milan (Italy)

*Corresponding author: Amanda Whittal - amanda.whittal@unibocconi.it

(2)

Appendix 1. Search strings

PubMed search strings:

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND rare disease*[Title/Abstract]);

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND RDT*[Title/Abstract];

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND orphan medicinal product [Title/Abstract];

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND OMP [Title/Abstract];

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND rare disease*[Title/Abstract]) AND challenge*[Title/Abstract]);

patient reported outcome measure*[Title/Abstract]) OR prom[Title/Abstract]) OR patient reported outcome*[Title/Abstract]) AND rare disease*[Title/Abstract]) AND recommend*[Title/Abstract]);

health technology assessment[Title/Abstract]) AND (appraisal*[Title/Abstract])) AND (rare disease*[Title/Abstract]);

health technology assessment[Title/Abstract]) AND (appraisal*[Title/Abstract])) AND (RDT*[Title/Abstract]);

health technology assessment[Title/Abstract]) AND (appraisal*[Title/Abstract])) AND (orphan medicinal product*[Title/Abstract]);

health technology assessment[Title/Abstract]) AND (appraisal*[Title/Abstract])) AND (OMP[Title/Abstract])

Grey literature searches:

using patient reported outcome measures in HTA for rare disease;

using patient reported outcome measures in health technology assessment for rare disease

Referenzen

ÄHNLICHE DOKUMENTE

Dänemark hat erfolgreich Empfehlungen für eine landesweite PROMs-Nutzung für mehrere Indikationen und Krankheitsbilder entwickelt sowie in einigen Regionen eine IT-Infrastruktur

• Document longitudinal measurement properties (construct validity, ability to detect change). • Document guidelines for interpretation of treatment benefit and relationship

Yilmaz et al. [42] reported worse SF-36 scores in all domains for 165 patients with TAK com- pared with 109 healthy controls; with the exception of the domain for mental health,

The objective was to compare reticulo-rumen volume assessed by computer tomography (CT) with post mortem measurement of reticulo-rumen content mass in dairy goats..

The methods tested on 20 Alpine goats (3 ± 0.6 years old; 226 ± 9 DIM; 47 to 72 kg of BW) were: adipose cell size; deuterium oxide dilution space (D2OS); 3-dimension (3D) imaging

Nguyen H, Butow P, Dhillon H, Morris L, Brown A, West K, Sundaresan P (2020) Using patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs) in routine head

This study presents a procedure of assessing suitability, adaptation and testing of the psychometric properties of two instruments (the Health Assessment Questionnaire Disability

This increase in the organic-to-inorganic ratio often had opposite effects on clarity according to different metrics, improving clarity in mid-Bay waters in terms of light